Literature DB >> 27070448

Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.

Jingwei Liu1, Shurong Zhang, Yuefeng Hu, Zhaomin Yang, Jingpo Li, Xuesong Liu, Lijuan Deng, Yue Wang, Xiaoyan Zhang, Ting Jiang, Xu Lu.   

Abstract

The paradoxical coexistence of spontaneous tumor antigen-specific immune response with progressive disease in cancer patients need to dissect the molecular pathways involved in tumor-induced T-cell dysfunction or exhaustion. Programmed cell death 1 (PD-1) has been identified as a marker of exhausted T cells in chronic disease states, and blockade of PD-1-PD-L1 interactions has been shown to partially restore T-cell function. We have found that T-cell immunoglobulin mucin (Tim) 3 is expressed on CD8+ tumor-infiltrating lymphocytes (TILs) isolated from patients with colorectal cancer. All T-cell immunoglobulin mucin 3 (Tim-3+) TILs coexpress PD-1, and Tim-3+ PD-1+ CD8+ TILs represent the predominant fraction of Tcells infiltrating tumors. Tim-3+PD-1+ CD8+ TILs exhibit the most severe exhausted phenotype as defined by failure to produce cytokines, such as interferon-γ, tumor necrosis factor-α, and interleukin-2. We further find that combined targeting of the Tim-3 and PD-1 pathways increased the frequencies of not only interferon-γ and tumor necrosis factor-α but also frequencies of proliferating tumor antigen-specific CD8+ T cells than targeting either pathway alone. A concomitant decrease in regulatory T cells and enhanced killing in a cytotoxicity assay was observed. Collectively, our findings support the use of Tim-3-Tim-3L blockade together with PD-1-PD-L1 blockade to reverse tumor-induced T-cell exhaustion/dysfunction in patients with colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27070448     DOI: 10.1097/CJI.0000000000000122

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  43 in total

1.  Intestinal Lamina Propria CD4+ T Cells Promote Bactericidal Activity of Macrophages via Galectin-9 and Tim-3 Interaction during Salmonella enterica Serovar Typhimurium Infection.

Authors:  Xin Yu; Hongru Zhang; Linyan Yu; Meifang Liu; Zengyan Zuo; Qiuju Han; Jian Zhang; Zhigang Tian; Cai Zhang
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

2.  T-cell phenotypes are associated with serum IgE levels in Amish and Hutterite children.

Authors:  Cara L Hrusch; Michelle M Stein; Justyna Gozdz; Mark Holbreich; Erika von Mutius; Donata Vercelli; Carole Ober; Anne I Sperling
Journal:  J Allergy Clin Immunol       Date:  2019-08-08       Impact factor: 10.793

Review 3.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

4.  An immunosuppressive scoring system to predict recurrence and assist in decision regarding postoperative adjuvant treatment in gastric cancer.

Authors:  Jiabin Wang; Qingzhu Qiu; Ningzi Lian; Huagen Wang; Qiaoling Zheng; Yinghong Yang; Yubin Ma; Yajun Zhao; Ping Li; Jianxian Lin; Jun Lu; Qiyue Chen; Longlong Cao; Mi Lin; Changming Huang; Jianwei Xie
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

5.  Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.

Authors:  Hadi Hassannia; Mitra Ghasemi Chaleshtari; Fatemeh Atyabi; Mahshid Nosouhian; Ali Masjedi; Mohammad Hojjat-Farsangi; Afshin Namdar; Gholamreza Azizi; Hamed Mohammadi; Ghasem Ghalamfarsa; Gholamabas Sabz; Sajad Hasanzadeh; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Immunology       Date:  2019-10-24       Impact factor: 7.397

6.  Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.

Authors:  Mengjia Song; Xinfeng Chen; Liping Wang; Yi Zhang
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

7.  Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.

Authors:  S Feola; C Capasso; M Fusciello; B Martins; S Tähtinen; M Medeot; S Carpi; F Frascaro; E Ylosmäki; K Peltonen; L Pastore; V Cerullo
Journal:  Oncoimmunology       Date:  2018-05-07       Impact factor: 8.110

Review 8.  Control of NK Cell Activation by Immune Checkpoint Molecules.

Authors:  Asma Beldi-Ferchiou; Sophie Caillat-Zucman
Journal:  Int J Mol Sci       Date:  2017-10-12       Impact factor: 5.923

9.  Early and Partial Reduction in CD4+Foxp3+ Regulatory T Cells during Colitis-Associated Colon Cancer Induces CD4+ and CD8+ T Cell Activation Inhibiting Tumorigenesis.

Authors:  Jonadab E Olguín; Itzel Medina-Andrade; Emmanuel Molina; Armando Vázquez; Thalia Pacheco-Fernández; Rafael Saavedra; Carlos Pérez-Plasencia; Yolanda I Chirino; Felipe Vaca-Paniagua; Luis E Arias-Romero; Emma B Gutierrez-Cirlos; Sonia A León-Cabrera; Miriam Rodriguez-Sosa; Luis I Terrazas
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

10.  miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion.

Authors:  Qing Li; Nathan Johnston; Xiufen Zheng; Hongmei Wang; Xusheng Zhang; Dian Gao; Weiping Min
Journal:  Oncotarget       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.